TrialMedicine2017

A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.

Zhifei Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.